BH
Buggana Hariharnath
About Buggana Hariharnath
Data last updated:
Buggana Hariharnath has 20 years in corporate governance. Holds Designated Partner and Nominee Director roles. Currently with 9 companies, including Invascent Advisory Services India Llp and Invascent Ilsf Manager Llp. Formerly with 11 companies, such as Strides Consumer Private Limited and Gland Pharma Ltd. Engaged in General Business, Healthcare. Contributes to corporate operations. The 7 current companies with reported revenue have a combined latest revenue of ₹1,600 Cr; the largest is Symbiotec Pharmalab Limited at ₹756 Cr (FY 2025).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Symbiotec Pharmalab Limited U24232MP2002PLC015293 | Nominee Director | 16 Sep 2024 | 2002 | ₹756 Cr (FY 2025) | Active |
 Maiva Pharma Private Limited U24231KA1993PTC013976 | Director | 13 Sep 2024 | 1993 | ₹399 Cr (FY 2025) | Active |
 Accumax Lab Devices Private Limited U33110GJ2009PTC056957 | Nominee Director | 04 Sep 2024 | 2009 | ₹256 Cr (FY 2025) | Active |
 Aurigene Oncology Limited U24239KA2001PLC029391 | Director | 30 Mar 2015 | 2001 | ₹172 Cr (FY 2025) | Active |
| Designated Partner | 19 Oct 2020 | 2020 | ₹10.68 Cr (FY 2021) | Active | |
 Maiva Lifesciences Private Limited U24110TN2022PTC154153 | Director | 05 Sep 2024 | 2022 | ₹5.70 Cr (FY 2025) | Active |
| Knovea Pharmaceutical Private Limited U24110MP2020PTC050978 | Nominee Director | 16 Sep 2024 | 2020 | ₹62.7 Lakh (FY 2025) | Active |
| Symbiotec Zenfold Private Limited U24100MP2020PTC052495 | Nominee Director | 16 Sep 2024 | 2020 | – | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 Strides Consumer Private Limited U24100MH2017PTC292022 | Director | 20 Dec 2018 | 2017 | ₹3.50 Cr (FY 2025) | Active |
 Gland Pharma Ltd L24239TG1978PLC002276 | Director | 22 Dec 2007 | 1978 | ₹6,747 Cr (FY 2026) | Active |
 Dr. Agarwal's Health Care Limited L85100TN2010PLC075403 | Director | 18 Jan 2011 | 2010 | ₹2,125 Cr (FY 2026) | Active |
| Suryateja Healthcare Private Limited U85100TG2014PTC093806 | Director | 01 Jun 2021 | 2014 | ₹14.87 Cr (FY 2025) | Active |
| Young President's Organisation Hyderabad Chapter U93000TG2007NPL055534 | Director | 06 Jul 2013 | 2007 | ₹4.52 Cr (FY 2026) | Active |
 Sahrudaya Health Care Private Limited U85100TG2011PTC072383 | Nominee Director | 13 Apr 2015 | 2011 | ₹1,837 Cr (FY 2025) | Active |
 Invascent Advisory Services India Private Limited U74140TG2006PTC050912 | Managing Director | 09 Sep 2006 | 2006 | ₹15.58 Cr (FY 2020) | Converted To Llp |
 Rajyalakshmi Healthcare Private Limited U85100TG2015PTC099232 | Director | 01 Jun 2021 | 2015 | ₹157 Cr (FY 2024) | Amalgamated |
| Total Prosthetics & Orthotics India Private Limited U33110HR2011PTC044590 | Nominee Director | 09 Jan 2015 | 2011 | ₹168 Cr (FY 2022) | Under Liquidation |
Explore Director's current and past company associations Uncover their professional journey today!
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Buggana Hariharnath
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Buggana Hariharnath
Buggana Hariharnath has 20 years in corporate governance. Holds Designated Partner and Nominee Director roles. Currently with 9 companies, including Invascent Advisory Services India Llp and Invascent Ilsf Manager Llp. Formerly with 11 companies, such as Strides Consumer Private Limited and Gland Pharma Ltd. Engaged in General Business, Healthcare. Contributes to corporate operations. The 7 current companies with reported revenue have a combined latest revenue of ₹1,600 Cr; the largest is Symbiotec Pharmalab Limited at ₹756 Cr (FY 2025).
Buggana Hariharnath is associated with 9 companies as Designated Partner and Nominee Director, including Symbiotec Pharmalab Limited (₹756 Cr), Maiva Pharma Private Limited (₹399 Cr), Accumax Lab Devices Private Limited (₹256 Cr).
Buggana Hariharnath has expertise in General Business, Healthcare.
Buggana Hariharnath has 20 years in corporate governance.
By reported revenue, the largest current company of Buggana Hariharnath is Symbiotec Pharmalab Limited, with revenue of ₹756 Cr (FY 2025).
The 7 current companies of Buggana Hariharnath that report revenue have a combined latest revenue of ₹1,600 Cr.
Buggana Hariharnath currently holds positions at 9 companies; the 5 largest by reported revenue are Symbiotec Pharmalab Limited (₹756 Cr), Maiva Pharma Private Limited (₹399 Cr), Accumax Lab Devices Private Limited (₹256 Cr), Aurigene Oncology Limited (₹172 Cr), Invascent Advisory Services India Llp (₹10.68 Cr).